-
Thrombosis of prosthetic heart valves is one of the most feared complications of heart-valve replacement.
-
Most prior study results of catheter ablation for atrial fibrillation (AF) have had relatively short follow-up duration.
-
Coronary artery anomalies are being recognized with increasing frequency due to the increased usage of computed tomography (CT) and magnetic resonance imaging (MRI) scans in patients with chest pain syndromes.
-
The randomized evaluation of long-term anticoagulation Therapy (RE-LY) trial was a study that compared two doses of a new direct-thrombin inhibitor, dabigatran, to warfarin for stroke prevention in patients with atrial fibrillation.
-
Mineralocorticoid receptor blockers have demonstrated improved survival in class III-IV heart-failure patients (spironolactone) and post-acute myocardial infarction patients with systolic dysfunction heart failure (eplerenone).
-
-
Escitalopram for menopausal hot flashes, rifaximin for IBS without constipation, herpes zoster vaccination, antiepileptics drugs and fracture risk, and FDA Actions.
-
The prognosis of older adults with AML even after intensive chemotherapy is poor. Kantarjian and colleagues evaluated 446 AML patients 70 years and older who underwent cytarabine-based intensive chemotherapy between 1900 and 2008.
-
Myelodysplastic syndromes (MDS) usually occur in older adults and, as such, comorbid conditions are common. The investigators found that among 418 MDS patients, at least one comorbid condition existed in 93% at diagnosis. Comorbidity scores were generated using three common scoring systems: the HCT-CI, MDS-CI, and CCI. Worse survival was linked to higher CCI (p = 0.01) and MDS-CI (p = 0.02) but not HCT-CI. Higher CCI scores were associated with non-leukemic death and progression of red blood cell dependency, whereas higher comorbidity by HCT-CI and MDS-CI did not. Higher comorbid burden by CCI in MDS predicts for worse survival and non-leukemic death. Comorbidity data may help refine prognosis for MDS patients.
-
Uric acid as a weak organic acid (pka 5.8) is poorly soluble at physiological pH.